Human papillomavirus vaccines and uses of the same

Inventors

Brough, Douglas E. • BOLINGER, Cheryl G. • Yarlagadda, Ramya • KURELLA, Vinodhbabu • Ponraj, Prabakaran • METENOU, Simon • Ding, Kuan-Fu

Assignees

Precigen Inc

Abstract

Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.

Core Innovation

The invention relates to a polynucleotide encoding a polypeptide construct comprising the amino acid sequence of SEQ ID NO: 52 or 54. The disclosure includes engineered viral vector architectures, including adenoviral vector formats derived from a gorilla adenovector, and promoter control using an immediate early cytomegalovirus (CMV) promoter [procedural detail omitted for safety].

The disclosure further describes engineered broad-spectrum human papillomavirus (HPV) molecular vaccine constructs comprising non-naturally occurring polynucleotides encoding modified HPV immune-response-inducing proteins. The constructs include HPV-16 and HPV-18 E5/E6/E7 variants with specific substitutions and deletions, and the immune-response-inducing proteins are fused to agonist peptides [procedural detail omitted for safety].

The disclosure also includes inducible regulation of heterologous gene expression by ligand-inducible ecdysone receptor (EcR)-based gene switch systems. Additional construct architectures include ankyrin-like repeat–HPV peptide fusions, multi-antigen linker-connected designs using KK linkers, and general cytokine co-expression concepts including IL-12 together with linker, IRES, and gene expression regulatory elements [procedural detail omitted for safety].

Claims Coverage

The provided claim coverage centers on one independent claim directed to a polynucleotide encoding a polypeptide construct comprising SEQ ID NO: 52 or 54, with dependent claim refinements involving gorilla adenoviral vector context, E1 and/or E4 deletions, and immediate early CMV promoter control.

The claim coverage focuses on a polynucleotide encoding a defined polypeptide construct sequence (SEQ ID NO: 52 or 54), with the construct placed in a gorilla adenoviral vector lacking E1 and/or E4 regions and controlled by an immediate early CMV promoter.

Stated Advantages

Documented Applications